Home » Clinical Trials » Leukemia » NCT03904069
NCT03904069

A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 Chimeric Antigen Receptor T-cell (CAR-T) AMG 553 in Subjects With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia.

Study Summary

Evaluate the safety and tolerability of AMG 553 in adult and adolescent subjects with FLT3-positive R/R AML. Determine the maximum tolerated cell dose (MTCD) or recommended phase 2 cell dose (RP2CD) of AMG 553.

Want to learn more about this trial?

Request More Info

Interventions

AMG 553DRUG
AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy

Study Locations

FacilityCityStateCountry
City of Hope National Medical CenterDuarteCaliforniaUnited States
Stanford UniversityPalo AltoCaliforniaUnited States
MD Anderson Cancer CenterHoustonTexasUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026